BL-1020

From Wikipedia, the free encyclopedia

BL-1020 is a new orally active antipsychotic for the possible treatment of schizophrenia and pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.[1] It is currently under Phase II/III trial phase.[2] It has been introduced by BioLineRx, a biopharmaceutical development company.

References

  1. ↑ Geffen, Y; Keefe, R; Rabinowitz, J; Anand, R; Davidson, M (September 2012). "Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.". The Journal of clinical psychiatry 73 (9): e1168–74. PMID 23059159. 
  2. ↑ Biolinerx (Jan 7, 2013). "BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug during week of March 18, 2013". Biolinerx. 
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.